Aidoc secures new FDA clearances for neurovascular and cardiovascular detection tools


Aidoc has announced it has increased its total number of US Food and Drug Administration (FDA) clearances to 11 with the addition of two new computed tomography (CT)-based artificial intelligence (AI) solutions for detecting all intracranial vessel occlusions, and aortic dissection (AD).

As per a company press release, these Aidoc solutions enable care teams across multiple service lines to not only identify patients in need of escalated care but further enhance cross-specialty provider workflows, leading to decreased time to treatment and improved transfers, which may result in additional care-improving procedures.

While existing products on the market detect only middle cerebral artery (MCA) M1 or internal carotid artery (ICA) occlusions, according to the release, Aidoc claims that its latest Vessel Occlusion (VO) solution makes it the first and only company to gain clearance for triage and notification of all intracranial large vessel occlusions (LVOs) and more distal medium vessel occlusions (MeVOs) in the MCA, ICA, anterior cerebral artery, posterior cerebral artery, vertebral artery and basilar artery.

Now, stroke teams have an option for an AI-driven workflow within a mobile app that provides reliable notification and convenient access to critical patient information and imaging for all LVO and MeVO patients—conditions where every minute matters, the release adds. With its ability to identify distal MeVOs that are more difficult to detect clinically and on imaging, Aidoc’s recently US FDA-cleared VO solution “empowers providers to swiftly triage these patients” who may qualify for meaningful surgical intervention.

“Ischaemic stroke caused by any large vessel occlusion can be potentially disabling,” said Joseph Schindler (Yale New Haven Hospital, New Haven, USA). “Time is still brain; thus, early detection with AI can be a gamechanger to quickly address distal or basilar artery occlusions that may benefit from acute stroke interventions.”

In addition, Aidoc has launched Aortic Solutions, which provides AI-powered, full-range aorta care for acute aorta teams to improve the acute treatment and long-term follow-up of cardiovascular patients. The latest US FDA clearance for both type A and type B AD triage is now available on Aidoc’s platform, which notifies multidisciplinary specialists on all relevant AD cases and allows for on-the-go, high-fidelity image review.

Aidoc claims to be “the only company with a proven EHR [electronic health record] integration for the population of critical, time-sensitive patient information on the app”. The release further notes that specialists can use this technology to collaborate more quickly and determine the best course of action for these emergency cases, and that the new Aortic Solutions offering supports a variety of workflows for all acute aortic conditions—including thoracic aortic aneurysm, abdominal aortic aneurysm, the newly cleared AI AD solution, and more.

“It is important for surgeons to have the best available tools to quickly identify and treat acute aorta patients,” said James McKinsey (Mount Sinai Healthcare System, New York, USA). “Aidoc’s acute aorta solution assesses every scan for acute aortic dissection and triages the positive cases, enables efficient communication and expedites workflows so specialists can collaborate for multidisciplinary decision-making to optimise timely care.”


Please enter your comment!
Please enter your name here